An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long-term safety and efficacy of three NRP104
doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of
adults with ADHD.